Gulf International Bank UK Ltd raised its position in shares of Illumina Inc. (NASDAQ:ILMN) by 0.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 44,340 shares of the life sciences company’s stock after buying an additional 350 shares during the period. Gulf International Bank UK Ltd’s holdings in Illumina were worth $8,054,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of ILMN. Physicians Financial Services Inc. boosted its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares during the period. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock valued at $110,000 after buying an additional 158 shares during the last quarter. Fuller & Thaler Asset Management Inc. purchased a new stake in shares of Illumina during the second quarter valued at approximately $112,000. Ropes Wealth Advisors LLC boosted its stake in shares of Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock valued at $121,000 after buying an additional 363 shares during the last quarter. Finally, Checchi Capital Advisers LLC boosted its stake in shares of Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock valued at $134,000 after buying an additional 22 shares during the last quarter. Institutional investors and hedge funds own 92.98% of the company’s stock.

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Illumina Inc. (NASDAQ:ILMN) traded up 0.76% on Tuesday, reaching $137.21. The company had a trading volume of 486,038 shares. Illumina Inc. has a 12 month low of $127.10 and a 12 month high of $196.47. The stock has a 50 day moving average of $139.08 and a 200 day moving average of $152.96. The firm has a market capitalization of $20.16 billion, a PE ratio of 46.04 and a beta of 1.24.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, November 1st. The life sciences company reported $0.97 EPS for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.10. The company had revenue of $607 million for the quarter, compared to analysts’ expectations of $628.06 million. Illumina had a return on equity of 23.76% and a net margin of 18.72%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.80 earnings per share. On average, analysts anticipate that Illumina Inc. will post $3.32 EPS for the current year.

WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2016/11/29/illumina-inc-ilmn-position-raised-by-gulf-international-bank-uk-ltd.html.

ILMN has been the subject of several research reports. Citigroup Inc. boosted their price target on Illumina from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, September 12th. Argus reiterated a “buy” rating and set a $170.00 price target (down from $205.00) on shares of Illumina in a research report on Friday, October 14th. Zacks Investment Research cut Illumina from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 19th. Canaccord Genuity set a $136.00 target price on Illumina and gave the company a “hold” rating in a report on Friday, October 7th. Finally, Vetr cut Illumina from a “strong-buy” rating to a “buy” rating and set a $154.48 target price for the company. in a report on Wednesday, October 19th. Four equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $152.88.

In related news, Director Daniel Bradbury sold 600 shares of the business’s stock in a transaction dated Wednesday, September 14th. The stock was sold at an average price of $171.25, for a total value of $102,750.00. Following the transaction, the director now owns 17,065 shares in the company, valued at $2,922,381.25. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Robert S. Epstein sold 300 shares of the business’s stock in a transaction dated Tuesday, September 20th. The stock was sold at an average price of $174.29, for a total value of $52,287.00. Following the completion of the transaction, the director now owns 6,924 shares in the company, valued at approximately $1,206,783.96. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.

5 Day Chart for NASDAQ:ILMN

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.